The modified Rodnan skin score (mRSS) is a measure of skin thickness and is used as a
primary or secondary outcome measure in clinical trials of systemic sclerosis (scleroderma) …

Christopher P. Denton1, Michael Hughes2, Nataliya Gak1, Josephine Vila3, Maya H. Buch4,
Kuntal Chakravarty1, Kim Fligelstone1, Luke L. Gompels5, Bridget Griffiths3, Ariane L …

The term 'sclerosing diseases of the skin'comprises specific dermatological entities, which
have fibrotic changes of the skin in common. These diseases mostly manifest in different …

Objective To determine the natural history and timing of severe involvement of the kidney,
heart, lung, gastrointestinal (GI) tract, and skin in patients with systemic sclerosis (SSc) and …

The Subcommittee members initially agreed on the concepts of disease activity, damage
and severity, defining severity as the total effect of disease on organ function. It was decided …

Objective Early diffuse scleroderma (systemic sclerosis; SSc) has no proven treatment. This
study was undertaken to examine the efficacy of methotrexate (MTX) in improving the skin …

Objective To evaluate CAT‐192, a recombinant human antibody that neutralizes
transforming growth factor β1 (TGFβ1), in the treatment of early‐stage diffuse cutaneous …

The fibrotic diseases encompass a wide spectrum of entities including such multisystemic
diseases as systemic sclerosis, nephrogenic systemic fibrosis and sclerodermatous graft …

Objective To study the clinical implications of a skin thickness score≥ 20 at first visit and of
softening of sclerodermatous skin in a cohort of systemic sclerosis (SSc) patients with diffuse …

Systemic sclerosis and autoimmune myositis are both associated with decreased quality of
life and increased mortality. Their prognosis and management largely depend on the …